FDA widens Vertex’s Casgevy use for paediatric patients
Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.
Cytiva Navigating cell therapy WP 4
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
UniQure to seek approval of Huntington’s gene therapy after FDA U-turn
ASCO26: In vivo oncology approaches continue to show promise
Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme
Non-viral gene therapies emerge as key players amid viral safety bottlenecks
Regeneron cuts White House pricing deal, offers new gene therapy for free
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
